In a recent study published in The Lancet , researchers investigated whether semaglutide is beneficial in persons with atherosclerotic cardiovascular disease and a history of heart failure. Study: Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial . Image Credit: MillaF/Shutterstock.
com Introduction The global surge in obesity prevalence has led to a rapid increase in diabetes and cardiovascular disease. Semaglutide is a glucagon-like peptide-1 receptor agonist that causes weight loss and reduces major adverse cardiovascular events (MACEs) in diabetes patients. Further, one trial observed that semaglutide reduced MACEs by 20% in non-diabetic patients with obesity/overweight and atherosclerotic cardiovascular disease.
The rise in obesity is also associated with an increased prevalence of heart failure. Most patients with obesity and heart failure have heart failure with preserved ejection fraction, which is likely causally related to the pathological outcomes of obesity. While heart failure subtypes (preserved and reduced ejection fractions) share multiple clinical features, their cause and treatment response vary.
About the study The present study examined the benefits of semaglutide in persons with heart failure and obesity. This was a prespecified analysis of the Semaglutide Effects on Heart Disease and Stroke in Patients with Obesity and Overweight (SELECT) trial. Eligible subjects were .